Stocks / Stock overview

SELLAS Life Sciences Group, Inc. (SLS)

Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.

$19.97Price
+168.22%Day change
$4.07BMarket cap
1Our articles

NasdaqCM · Price as of · Delayed Quote

Stock Scorer
C48/100
  • Profitability0/20

    Losing money: $-35.8M net income over the last four reported quarters.

  • Insider buying vs selling15/20

    The last 1 Form 4s show no open-market buys or sells (grants and option exercises don't count either way). Neutral. Separately, 3 new 5%+ stake disclosures (13D/13G) hit in the last 6 months, which is big-money accumulation.

  • Dilution and offerings1/15

    Share count up 43.1% in a year and 1 offering-related filing. Heavy dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.

See the full breakdown
Analyst consensus
Strong buy$32.50
  • Analysts2
  • Implied upside+62.8%
  • Target range$30.00 to $35.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
SLS past month+92.2%
SLS closed at $20.16 on Nov 17, up 92.2% since Oct 19.$20.16$7.47Oct 19Nov 17
Close 20-day average 50-day average 200-day average

SLS closed at $20.16 on Nov 17, up 92.2% since Oct 19. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is above the 200-day (uptrend structure); trading at 100% of the 52-week range ($1.39 to $20.16).

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
8-KNovember 17, 2026FORM 8-K
8-KNovember 12, 20268-K
10-QNovember 12, 202610-Q
SCHEDULE 13GNovember 10, 2026View on EDGAR
SCHEDULE 13G/AOctober 27, 2026View on EDGAR
8-KAugust 11, 20268-K
10-QAugust 11, 202610-Q
SCHEDULE 13GAugust 7, 2026View on EDGAR
All SEC filings

SELLAS Life Sciences news

Sellas (SLS) shares more than double after its leukemia vaccine extended survival in a Phase 3 trial
News

Sellas (SLS) shares more than double after its leukemia vaccine extended survival in a Phase 3 trial

Sellas Life Sciences' galinpepimut-S vaccine met the overall survival goal of its 126-patient REGAL trial in acute myeloid leukemia. The confidence intervals and secondary results haven't been released yet.

Nov 17, 2026

Frequently asked questions

What do analysts expect for SLS?

2 analysts cover SELLAS Life Sciences Group, Inc. (SLS). The consensus rating is Strong buy. The average price target is $32.50, in a range of $30.00 to $35.00.

Are insiders buying or selling SLS?

We have no qualifying Form 4 insider purchases or sales on record for SELLAS Life Sciences Group, Inc. (SLS). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see SLS SEC filings?

Recent filings are listed on this page, newest first. The latest is an 8-K filed November 17, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.